Committed to trials of Low Dose Naltrexone as a treatment for autoimmune diseases

Text Resize

-A +A
Low Dose Naltrexone (LDN) is a drug that may help regulate a dysfunctional immune system in autoimmune diseases.

About LDN Research Trust

The primary aim of the Trust is to initiate Clinical Trials of Low Dose Naltrexone, help and support those who have a condition where LDN could be of benefit obtain a prescription around the world.

Download the LDN Information Pack which can be printed, to show your doctor.

Whilst working to raise funds for trials, we have helped over 15,000 people  to obtain LDN from a General Practitioner or Neurologist, either through the National Health Service or by private prescription.  We have also been able to help people, not just in the UK but in countries throughout Europe, as well as USA, Canada, West Indies, Australia, New Zealand, and others. 

Find out more

LDN Aware

The mission of LDN aware is to spread public awareness of LDN worldwide.

Low dose naltrexone, where naltrexone is used in doses approximately one-tenth those used for drug/alcohol rehabilitation purposes, is being used as an "off-label" treatment for certain immunologically-related disorders. The use of LDN for such diseases as cancer was first proposed by Ian Zagon, PhD, and LDN's broader clinical effects in humans were proposed by Bernard Bihari, MD.  

Find out more

Sign up to our Newsletter

The LDN 2014 AIIC Conference 7th/8th November 2014

The LDN 2014 AIIC Conference is a charity event organised by the LDN Research Trust, Venue: the MEET Las Vegas, 7th/8th November 2014.

Full details including prices and times available here.

This conference reviews, compares and contrasts the most recent data and treatments for a variety of Auto-Immune and Immuno-modulated Conditions.


Featured Video